Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2 Not yet recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06387628 2024-08-02

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Phase 2 Recruiting

74 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

54 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06202313 2024-01-11

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2 Not yet recruiting

128 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03579472 2022-10-31

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1 Terminated

38 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

40 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05402722 2022-06-02

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

Phase 1/2 Completed

258 enrolled 18 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

Phase 3 Completed

622 enrolled 26 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04913571 2021-06-04

TEMPLATE

Phase 2 Unknown

265 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

160 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04502680 2020-08-11

EMBRAVE-001

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01372579 2019-06-07

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02225470 2018-08-28

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Phase 3 Completed

530 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02616848 2015-11-30

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Phase 1 Unknown

1 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

PATHFINDER

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

ENHANCE-1

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

KEYNOTE-119

TEMPLATE

GEP

EMBRAVE-001

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers